Clinical Trial Update: Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating safety and efficacy of anti-GPRC5D CAR-T cells for relapsed/refractory multiple myeloma. Details on results are not provid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• anti-GPRC5D CAR-T cells (CAR-T therapy targeting GPRC5D)

Snippet

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1, Phase 2 | Status: UNKNOWN